Get the Stockscreener App
1.33
3.62%
-0.05
Pre-market:
1.32
-0.01
-0.75%
Fibrobiologics Inc stock is traded at $1.33, with a volume of 164.90K.
It is down -3.62% in the last 24 hours and down -3.62% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$1.38
Open:
$1.42
24h Volume:
164.90K
Relative Volume:
0.49
Market Cap:
$6.93M
Revenue:
-
Net Income/Loss:
$-18.68M
P/E Ratio:
-0.1799
EPS:
-7.3948
Net Cash Flow:
$-15.70M
1W Performance:
-2.21%
1M Performance:
-3.62%
6M Performance:
-82.04%
1Y Performance:
-93.01%
1-Day Range:
$1.31
$1.425
1-Week Range:
$1.25
$1.51
52-Week Range:
$1.03
$22.60
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.33 | 6.93M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Canada
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics CEO Issues Letter to Shareholders - GlobeNewswire
FibroBiologics Grants Stock Options to Key Executives - TipRanks
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics (FBLG) CEO receives 92,410 options vesting over 4 years - Stock Titan
FibroBiologics (FBLG) CSO granted 61,607 stock options at $1.38 - Stock Titan
FibroBiologics (FBLG) CFO awarded 61,607 stock options at $1.38 - Stock Titan
FibroBiologics grants options to general counsel | FBLG Insider Trading - Stock Titan
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com Australia
FibroBiologics reports preclinical burn wound treatment results - Investing.com
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring - The Manila Times
In mice, a topical cell treatment eased burn inflammation in 8 days - Stock Titan
Maxim Group Downgrades FibroBiologics(FBLG.US) to Hold Rating - Moomoo
FibroBiologics releases first batch of diabetic ulcer drug By Investing.com - Investing.com Australia
FibroBiologics releases first batch of diabetic ulcer drug - Investing.com
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - The Manila Times
Diabetic foot ulcer trial nears enrollment as drug batch clears tests - Stock Titan
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
Certain Common Stock of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
Certain Stock Options of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens - TipRanks
FibroBiologics Launches New At-The-Market Equity Offering - TipRanks
Regenerative medicine company FibroBiologics (stock code: FBLG) recently filed documents with the U.S. Securities and Exchange Commission (SEC), announcing that it has signed an At Market Issuance (ATM) agreement. - Bitget
[424B5] FibroBiologics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
FibroBiologics (NASDAQ: FBLG) sets up $6,150,000 at-the-market stock program - Stock Titan
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update - The Manila Times
FibroBiologics Reports Q1 2026 Financial Results and Corporate Updates on Clinical Advancements - Quiver Quantitative
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FibroBiologics (FBLG) low cash, $5M loss and going concern risk - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Preclinical psoriasis data from FibroBiologics heads to Chicago meeting - Stock Titan
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 - The Manila Times
FibroBiologics (FBLG) price target decreased by 76.25% to 19.38 - MSN
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics (FBLG) price target increased by 1,584.21% to 81.60 - MSN
Return on invested capital % of FibroBiologics, Inc. – LSX:A426UV - TradingView
FibroBiologics (FBLG) asks shareholders to OK March warrant issuances, equity plan - Stock Titan
FibroBiologics regains Nasdaq compliance on listing standards By Investing.com - Investing.com India
FibroBiologics regains Nasdaq compliance on listing standards - Investing.com
FibroBiologics Secures Nasdaq Listing Compliance, Under Monitoring - TipRanks
Fibrobiologics compliant with all Nasdaq listing requirements - marketscreener.com
FibroBiologics confirms Nasdaq compliance; listing matter closed, one-year monitors remain - TradingView
FibroBiologics Compliant with All Nasdaq Listing Requirements - TradingView
FibroBiologics (Nasdaq: FBLG) clears listing issues but faces one-year monitor - Stock Titan
FibroBiologics Lowers Quorum Requirement in Amended Bylaws - TipRanks
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):